ICP
DNA icon

Interchange Capital Partners’s Ginkgo Bioworks DNA Stock Holding History

Interchange Capital Partners’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,753
Closed -$19.6K – 291
2024
Q2 		$19.6K Buy
4,753
+602
+15% +$18K 0.01% 279
2024
Q1 		$203K Buy
4,151
+980
+31% +$50.7K 0.14% 162
2023
Q4 		$215K Buy
3,171
+461
+17% +$28.2K 0.16% 139
2023
Q3 		$196K Buy
2,710
+333
+14% +$26.6K 0.16% 145
2023
Q2 		$177K Buy
2,377
+1,557
+190% +$92.2K 0.13% 146
2023
Q1 		$43.6K Buy
820
+179
+28% +$11.3K 0.02% 215
2022
Q4 		$43.3K Sell
641
-466
-42% -$42.9K 0.04% 125
2022
Q3 		$138K Buy
1,107
+34
+3% +$4.05K 0.15% 146
2022
Q2 		$102K Buy
1,073
+259
+32% +$31.6K 0.11% 151
2022
Q1 		$131K Buy
+814
New +$158K 0.13% 154

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Interchange Capital Partners's DNA Position: Q3 2024 in Review

Interchange Capital Partners sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 4,753 shares — an estimated $19.6K sold.

Interchange Capital Partners first reported a position in DNA in Q1 2022 and held it in 10 quarters. The position peaked at $215K in Q4 2023. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • Interchange Capital Partners reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • Interchange Capital Partners sold 4,753 Ginkgo Bioworks shares in Q3 2024, an estimated $19.6K.
  • Interchange Capital Partners first reported a position in Ginkgo Bioworks in Q1 2022 and held it in 10 quarters.
  • Interchange Capital Partners's Ginkgo Bioworks position peaked at $215K in Q4 2023.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Interchange Capital Partners's 13F filing for Q3 2024, filed 28 Oct 2024.